Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02

Phioanh Leia Nghiemphu; Victoria Asuquo Ebiana; Patrick Wen; Mark Gilbert; Lauren E. Abrey; F. Lieberman; Lisa M. DeAngelis; H. Ian Robins; W. K. Alfred Yung; Susan Chang; Jan Drappatz; Minesh P. Mehta; Victor A. Levin; Kenneth Aldape; Janet E. Dancey; J. J. Wright; Michael Prados; John Kuhn; Timothy F. Cloughesy

doi:10.1007/s11060-017-2624-4

Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02

Phioanh Leia Nghiemphu, Victoria Asuquo Ebiana, Patrick Wen, Mark Gilbert, Lauren E. Abrey, F. Lieberman, Lisa M. DeAngelis, H. Ian Robins, W. K. Alfred Yung, Susan Chang, Jan Drappatz, Minesh P. Mehta, Victor A. Levin, Kenneth Aldape, Janet E. Dancey, J. J. Wright, Michael Prados, John Kuhn, Timothy F. Cloughesy

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of neuro-oncology
DOIs	https://doi.org/10.1007/s11060-017-2624-4
State	Published - Jul 10 2017

Disciplines

Pharmacology
Medicine and Health Sciences
Endocrinology
Surgery

Access to Document

10.1007/s11060-017-2624-4License: Unspecified

Cite this

Nghiemphu, P. L., Ebiana, V. A., Wen, P., Gilbert, M., Abrey, L. E., Lieberman, F., DeAngelis, L. M., Robins, H. I., Yung, W. K. A., Chang, S., Drappatz, J., Mehta, M. P., Levin, V. A., Aldape, K., Dancey, J. E., Wright, J. J., Prados, M., Kuhn, J., & Cloughesy, T. F. (2017). Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02. Journal of neuro-oncology. https://doi.org/10.1007/s11060-017-2624-4

Nghiemphu, PL, Ebiana, VA, Wen, P, Gilbert, M, Abrey, LE, Lieberman, F, DeAngelis, LM, Robins, HI, Yung, WKA, Chang, S, Drappatz, J, Mehta, MP, Levin, VA, Aldape, K, Dancey, JE, Wright, JJ, Prados, M, Kuhn, J & Cloughesy, TF 2017, 'Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02', Journal of neuro-oncology. https://doi.org/10.1007/s11060-017-2624-4

@article{f83783062a324504b9447d9bd1693d56,

title = "Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02",

author = "Nghiemphu, {Phioanh Leia} and Ebiana, {Victoria Asuquo} and Patrick Wen and Mark Gilbert and Abrey, {Lauren E.} and F. Lieberman and DeAngelis, {Lisa M.} and Robins, {H. Ian} and Yung, {W. K. Alfred} and Susan Chang and Jan Drappatz and Mehta, {Minesh P.} and Levin, {Victor A.} and Kenneth Aldape and Dancey, {Janet E.} and Wright, {J. J.} and Michael Prados and John Kuhn and Cloughesy, {Timothy F.}",

note = "Recurrent glioblastoma (GBM) has a very low 6-month progression free survival (PFS) with currently available treatments. Combination chemotherapy to target multiple cell signaling pathways is currently being investigated in order to improve prognosis for recurrent disease. The purpose of this phase I study was to determine the maximum tolerated dose (MTD) for the combination of tipifarnib and sorafenib for the treatment of recurrent GBM.",

year = "2017",

month = jul,

day = "10",

doi = "10.1007/s11060-017-2624-4",

language = "American English",

journal = "Journal of neuro-oncology",

}

TY - JOUR

T1 - Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02

AU - Nghiemphu, Phioanh Leia

AU - Ebiana, Victoria Asuquo

AU - Wen, Patrick

AU - Gilbert, Mark

AU - Abrey, Lauren E.

AU - Lieberman, F.

AU - DeAngelis, Lisa M.

AU - Robins, H. Ian

AU - Yung, W. K. Alfred

AU - Chang, Susan

AU - Drappatz, Jan

AU - Mehta, Minesh P.

AU - Levin, Victor A.

AU - Aldape, Kenneth

AU - Dancey, Janet E.

AU - Wright, J. J.

AU - Prados, Michael

AU - Kuhn, John

AU - Cloughesy, Timothy F.

N1 - Recurrent glioblastoma (GBM) has a very low 6-month progression free survival (PFS) with currently available treatments. Combination chemotherapy to target multiple cell signaling pathways is currently being investigated in order to improve prognosis for recurrent disease. The purpose of this phase I study was to determine the maximum tolerated dose (MTD) for the combination of tipifarnib and sorafenib for the treatment of recurrent GBM.

PY - 2017/7/10

Y1 - 2017/7/10

UR - https://link.springer.com/content/pdf/10.1007%2Fs11060-017-2624-4.pdf

U2 - 10.1007/s11060-017-2624-4

DO - 10.1007/s11060-017-2624-4

M3 - Article

JO - Journal of neuro-oncology

JF - Journal of neuro-oncology

ER -

Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02

Disciplines

Access to Document

Other files and links

Cite this